Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 52 min ago
Peer-reviewedCC BY-NC-ND 4.0BMC Pulmonary Medicine

EGFR-mutant lung adenocarcinoma featuring massive bronchorrhea, a dominant pulmonary nodule, and migratory ground-glass opacities: a case report and literature review

  1. 1Department of Breast Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003 China
  2. 2Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003 China
  3. 3Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003 China

Abstract

Background: Lung cancer exhibits profound clinical, radiological, and biological heterogeneity, which poses significant challenges for early recognition and timely diagnosis in select atypical cases. Among rare manifestations, massive bronchorrhea caused by EGFR-mutated lung adenocarcinoma with radiological findings of a dominant pulmonary nodule and migratory ground-glass opacities (GGOs) remains extremely uncommon.

Case presentation: A 67-year-old male patient presented with massive bronchorrhea and progressive dyspnea. Serial chest computed tomography (CT) scans revealed bilateral migratory GGOs and a small nodular lesion in the basal segment of the right lower lobe. Empiric antibiotic therapy and subsequent systemic corticosteroid treatment failed to alleviate his respiratory symptoms. Ultimately, markedly elevated sputum carcinoembryonic antigen (CEA) levels, combined with pathological results from transbronchial biopsy of the right lung nodule, confirmed a diagnosis of EGFR-mutated lung adenocarcinoma. Treatment with osimertinib achieved rapid resolution of bronchorrhea, accompanied by complete regression of the pulmonary nodule and GGOs during clinical follow-up.

Conclusions: Clinicians should maintain a high index of suspicion for lung adenocarcinoma in patients with persistent unexplained bronchorrhea. For patients harboring EGFR-sensitive mutations, EGFR tyrosine kinase inhibitors (TKIs) remain the first-line treatment, yielding favorable therapeutic effects on bronchorrhea control and improving survival outcomes.

Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12890-026-04574-8.

Related

  1. Keratin 17 Defines an Epithelial-Mesenchymal Transition-Associated Migratory Cell State in Pancreatic Ductal Adenocarcinoma
    Shayan Sarkar, Monisankar Ghosh, Lyanne Delgado-Coka +10
    bioRxivPreprintAll rights reservedFull textOncologybioRxivPMC
  2. Leptomeningeal metastasis of lung adenocarcinoma presenting as cauda equina syndrome: a case report and literature review
    Xiaofeng Chen, Haijuan Lv
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMC
  3. Synchronous lung adenocarcinoma and pulmonary carcinoid tumorlets in different lobes: a case report
    Yan-Qing Li, Yan-Zhao Xu
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMC
  4. Integrating multimodal data for precise subtyping and prognostication in patients with pulmonary mucinous adenocarcinoma
    Weiwei Yang, Chen Chen, Lue Li +5
    Translational cancer researchPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  5. A solitary brain metastasis from gastroesophageal junction adenocarcinoma 13 years after curative multimodality treatment: a case report and review of the literature
    Sara Di Lorenzo, Pasqualina Giordano, Giuseppe Catapano +6
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMCPMC
BibTeX
@article{chen2026egfrmutant,
  title = {{EGFR-mutant lung adenocarcinoma featuring massive bronchorrhea, a dominant pulmonary nodule, and migratory ground-glass opacities: a case report and literature review}},
  author = {Luyan Chen and Bing Yan and Shusen Zheng and Liangjie Fang},
  journal = {BMC Pulmonary Medicine},
  year = {2026},
  month = aug,
  doi = {10.1186/s12890-026-04574-8},
  url = {https://doi.org/10.1186/s12890-026-04574-8},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - EGFR-mutant lung adenocarcinoma featuring massive bronchorrhea, a dominant pulmonary nodule, and migratory ground-glass opacities: a case report and literature review
AU  - Luyan Chen
AU  - Bing Yan
AU  - Shusen Zheng
AU  - Liangjie Fang
PY  - 2026
DA  - 2026/08/12
JO  - BMC Pulmonary Medicine
DO  - 10.1186/s12890-026-04574-8
UR  - https://doi.org/10.1186/s12890-026-04574-8
AB  - Background: Lung cancer exhibits profound clinical, radiological, and biological heterogeneity, which poses significant challenges for early recognition and timely diagnosis in select atypical cases. Among rare manifestations, massive bronchorrhea caused by EGFR-mutated lung adenocarcinoma with radiological findings of a dominant pulmonary nodule and migratory ground-glass opacities (GGOs) remains extremely uncommon.  Case presentation: A 67-year-old male patient presented with massive bronchorrhea and progressive dyspnea. Serial chest computed tomography (CT) scans revealed bilateral migratory GGOs and a small nodular lesion in the basal segment of the right lower lobe. Empiric antibiotic therapy and subsequent systemic corticosteroid treatment failed to alleviate his respiratory symptoms. Ultimately, markedly elevated sputum carcinoembryonic antigen (CEA) levels, combined with pathological results from transbronchial biopsy of the right lung nodule, confirmed a diagnosis of EGFR-mutated lung adenocarcinoma. Treatment with osimertinib achieved rapid resolution of bronchorrhea, accompanied by complete regression of the pulmonary nodule and GGOs during clinical follow-up.  Conclusions: Clinicians should maintain a high index of suspicion for lung adenocarcinoma in patients with persistent unexplained bronchorrhea. For patients harboring EGFR-sensitive mutations, EGFR tyrosine kinase inhibitors (TKIs) remain the first-line treatment, yielding favorable therapeutic effects on bronchorrhea control and improving survival outcomes.  Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12890-026-04574-8.
SN  - 1471-2466
ER  -